Therefore, based on this work, using bromodomain inhibitors to target the upregulation of HO-1 in pancreatitis, especially in patients with KRAS mutations or precursor lesions, might become a strategy to delay the initiation or progression of pancreatic cancer. This evidence concerns the gene KRAS and pancreatitis.